Stocks · News reference

Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Partner Refiles Tabelecleucel Biologics License Application With FDA

Sep 30, 2026, 12:09 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 14, 2026, 12:08 PMBenzinga Newsdesk
Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
ATRA
BenzingaAug 12, 2026, 8:25 PMBenzinga Newsdesk
Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 268.42 percent decrease over earnings of $0.19 per share from the same period last
ATRA
SEC EDGARAug 12, 2026, 8:10 PMSEC EDGAR
8-K filing — Atara Biotherapeutics, Inc. (ATRA)
Filed: 2026-08-12 AccNo: 0001193125-26-346857 Size: 455 KB Item 2.02: Results of Operations and Financial Condition
ATRA